04-c-„FŒ{›xŒ¾-4.01



Similar documents
03-b-„FŒ{›xŒ¾-4.02

Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent

CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote

1272 CHEMOTHERAPY MAR. 1975

CHEMOTHERAPY

epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia

Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S.

THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium xerosis 10Š, Corynebacterium pseudodiphtheriticum 10Š, Corynebacterium

VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega

CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus

VOL. 43 NO. 4

Hisao Takayasu Department of Urology, Faculty of Medicine, University of Tokyo Masaaki Ohkoshi Department of Urology, Tokai University School of Medic

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec DNA 2, , % 1.65% 1.17% 90% 9 Escherichia coli -



Fig. 1 Chemical structure of DL-8280

VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human

pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P.

CHEMOTHERAPY DEC (NFLX), ofloxacin (OFLX), ciprofloxacin (CPFX) Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecali


CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study

Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml

Fig. 1 Chemical structure of KW-1070

988 CHEMOTHERAPY NOV. 1971

Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection

Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone

Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec LVFX 100 mg 3 / mg 2 / LVFX PK PD mg mg 1 1 AUC/MIC

CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates

semen quality or those without WBC in semen. In the patients with azoospermia and normal FSH levels (normogonadotropic azzospermia), the antibody (IgG

Title 尿路感染症分離菌の年次的変遷と薬剤感受性の検討 ( ニューキノロン系を中心として ) 深津, 英捷 ; 本多, 靖明 ; 水本, 裕之 ; 瀧, 知弘 ; 三井, Author(s) 々村, 仁志 ; 羽田野, 幸夫 ; 平岩, 親輔 ; 吉川, 和宏 ; 山田彰 ; 瀬川, 昭夫 Ci


CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX

VOL.42 S-1

CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin


VOL.48 NO.7 lase negative staphylococci, Escherichia coli, Klebsiella spp., Citrobacter freundii, Enterobacter spp., indole-positive Proteus, Serratia


Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII (45)

Table 1 Classification of female patients with vesical irritating symptom by their signs : Urinary pain with or without other vesical irritability. s

Fig. 1 Clinical findings and extent of inflammation area in female urethrocystitis Fig. 2 Classification and distribution of female patients with blad


CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin

VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneum


VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )

coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F


Table1MIC of BAY o 9867 against standard strains



CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz


VOL. 23 NO. 3 CHEMOTHERAPY 1379 Table 1 Susceptibility of clinical isolated strains to Tobramycin

CHEMOTHERAPY APR Fig. 2 The inactivation of aminoglycoside antibiotics by PC-904 Fig. 3 Serum concentration of PC-904 (1) Fig. 4 Urinary recover

CHEMOTHERAPY

Title 泌尿器科領域に於ける17-Ketosteroidの研究 17-Ketosteroidの臨床的研究 第 III 篇 : 尿 Author(s) 卜部, 敏入 Citation 泌尿器科紀要 (1958), 4(1): 3-31 Issue Date URL


Key words : candidemia, endotoxin, D-arabinitol, Candida antigen, serological examination

Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-

PCG = Benzylpenicillin ABPC= Ampicillin AMPC= Amoxicillin MPIPC = Oxacillin MCIPC = Cloxacillin SBPC= Sulbenicillin PIPC= Piperacillin



Fig. 1 Chemical structure of norfioxacin (AM-715)


VOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus


CHEMOTHERAPY

CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle


VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT against standard strains




2108 CHEMOTHERAPY SEPT Table 1 Antimicrobial spectrum Fig. 1

Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis

400 CHEMOTHERAPY JAN Table 1 Cases of drop outs

日本職業・災害医学会会誌第51巻第1号

02-(a)-Łi’ì™·Łv-4.11

indd

Therapy for Asthenopia in Cases of Convergence Insufficiency Hiroko TAKASAKI, C.O.J., Nobuko INAGAMI, C.O.J., and Kayoko TAKENAWA, C.O.J.. Orthoptic c

Yogo


Table 1 Profiles of 28 patients with Legionella pneumonia in Japan, a) Y Taguchi, personal communication b) M. Hayase, personal communicatio

Fig.1 Chemical structure of BAY o 9867

Oct THE JAPANESE JOURNAL OF ANTIBIOTICS Pseudomonas aeruginosa 186 P. aeruginosa piperacillin PIPC, taz


表紙PDF作成用/PDF表紙作成用




Physical and Psychological Effects of Stressors in Female College Students Reizou Mita*1, Konosuke Tomabechi*1, Isao Yamaguchi*1, Naoko Soeno*1, Shuhe

VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St

CHEMOTHERAPY DEC phvlococcus aureus Staphylococcus Enterococcus faecalis Escherichia Klebsiella pneumoniae Serratia marcescens Pseudomonas cepac

日本化学療法学会雑誌第61巻第6号

The Journal of the Japan Academy of Nursing Administration and Policies Vol 7, No 2, pp 19 _ 30, 2004 Survey on Counseling Services Performed by Nursi

Microsoft Word - Supplementary Information(Miura)ver2.docx


The Journal of the Japan Academy of Nursing Administration and Policies Vol 12, No 1, pp 49 59, 2008 資料 看護師におけるメンタリングとキャリア結果の関連 Relationship between M


Transcription:

544( 56 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 Dec. 25 2003 2. * *

Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 545( 57 ) 9 5 2003 8 2004 714 565 719 50 20 39 0 9 70 79 44.4 91.7% Escherichia coli Pseudomonas aeruginosa Enterococcus faecalis E. coli P. aeruginosa E. faecalis E. coli 40% E. coli E. coli P. aeruginosa E. faecalis P. aeruginosa E. coli P. aeruginosa E. faecalis

546( 58 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 Dec. 1 23) 2003 8 2004 714 565 719 1 3 I. 1. Fig. 1 41.8% (236/565) 58.2% (329/565) 50 12.7% (30/236) 26.7% (8/30) 60.0% (18/30) 13.3% (4/30) 50 70 79 35.6% (84/236) 10 19 60 79 48.0% (158/329) 0 9 70 79 44.4 91.7% 2. Fig. 2 Escherichia coli 51.7% 23.5% 13.6% Pseudomonas aeruginosa 2.9% 7.9% 13.6% Enterococcus faecalis 8.8% 12.6% 21.5% 3. Fig. 3 Fig. 3 1 E. coli 20 41.2%, 20 49 61.1% 50 69 48.7%, 7048.0% E. faecalis 20 5.9%, 20 49 4.2%, 50 69 10.5%, 70 12.0% Fig. 3 2 E. coli 2036.4%, 20 49 27.6%, 50 69 25.5%, 7020.5% E. faecalis 20 27.3%, 20 49 10.3%, 50 69 8.5%, 70 14.7% E. coli P. aeruginosa Fig. 3 3 50 69 70 E. faecalis 50 69 22.5%, 70 18.5% E. coli, P. aeruginosa, S. aureus

Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 547( 59 ) Fig. 1. 2003

548( 60 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 Dec. Fig. 2. 2003

Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 549( 61 ) Fig. 3. 2003

550( 62 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 Dec. 4. 1 Fig. 4 153 87 E. coli 50.3%54.0% P. aeruginosa 2.0% 4.6% E. faecalis 9.2% 8.0% 249 53 E. coli E. faecalis 25.7%, 12.4% 13.2% E. coli P. aeruginosa S. aureus 6.4%, 6.4% 15.1%, 7.5% 107 70 P. aeruginosa 10.3% 18.6% E. coli S. aureus 16.8%, 11.2%, 8.6%, 7.1% E. faecalis 20.6% 22.9% 5. Fig. 5 54186 E. coli E. faecalis 33.3% 14.8% E. coli 57.0% 6 Klebsiella spp., Proteus spp., Enterobacter spp., P. aeruginosa, S. aureus, E. faecalis 166136 E. coli, E. faecalis, P. aeruginosa 22.3%, 13.9%, 11.4% E. coli, E. faecalis, S. aureus 25.0%, 11.0%, 7.4% 12453 E. faecalis 25.0% P. aeruginosa 14.5% E. coli 17.0% E. faecalis 13.2% II. 1 23) 2003 8 2004 714 565719 50 12.7%, 20 5.2% 20 29 10 19 E. coli

Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 551( 63 ) Fig. 4. 2003

552( 64 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 Dec. Fig. 5. 2003

Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 553( 65 ) P. aeruginosa E. faecalis P. aeruginosa E. coli 20 49 61.1% E. faecalis E. coli E. faecalis 50 69 E. coli P. aeruginosa E. faecalis 20 49 E. faecalis 55.6% E. coli P. aeruginosa E. coli P. aeruginosa E. coli Klebsiella spp., P. aeruginosa, E. faecalis E. coli, E. faecalis P. aeruginosa E. coli, E. faecalis E. coli P. aeruginosa P. aeruginosa E. faecalis E. coli, P. aeruginosa, E. faecalis 1) E.coli, Klebsiella, Citrobacter Proteus Jpn. J. Antibiotics 34: 959 975, 1981 2) Escherichia coli, Klebsiella, Citrobacter Proteus 3 1981 3. Jpn. J. Antibiotics 36: 1521 1543, 1983 3) 4 1982 2. Jpn. J. Antibiotics 37: 723 733, 1984 4) 5 1983 2. Jpn. J. Antibiotics 38: 2230 2241, 1985 5) 6 1984 2. Jpn. J. Antibiotics 39: 3007 3018, 1986 6) 7 1985 2. Jpn. J. Antibiotics 40: 2013 2025, 1987 7) 8 1986 2. Jpn. J. Antibiotics 42: 2175 2188, 1989 8) 9 1987 2. Jpn. J. Antibiotics 43: 954 967, 1990 9) 10 1988 2. Jpn. J. Antibiotics 45: 1103 1111, 1992 10) 11 1989 2. Jpn. J. Antibiotics 48: 1161 1173, 1995 11) 12 1990 2. Jpn. J. Antibiotics 48: 1317 1328, 1995 12) 13 1991 2. Jpn. J. Antibiotics

554( 66 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 Dec. 48: 1422 1435, 1995 13) 14 1992 2. Jpn. J. Antibiotics 48: 1658 1670, 1995 14) 15 1993 2. Jpn. J. Antibiotics 48: 1788 1801, 1995 15) 16 1994 2. Jpn. J. Antibiotics 49: 494 508, 1996 16) 17 1995 2. Jpn. J. Antibiotics 50: 251 264, 1997 17) 18 1996 2. Jpn. J. Antibiotics 51: 112 129, 1998 18) 19 1997 2. Jpn. J. Antibiotics 52: 130 145, 1999 19) 20 1998 2. Jpn. J. Antibiotics 53: 234 248, 2000 20) 21 1999 2. Jpn. J. Antibiotics 54: 217 299, 2001 21) 22 2000 2. Jpn. J. Antibiotics 55: 399 411, 2002 22) 23 2001 2. Jpn. J. Antibiotics 56: 396 423, 2003 23) 24 2002 2. Jpn. J. Antibiotics 57: 275 287, 2004 COMPARATIVE STUDIES ON ACTIVITIES OF ANTIMICROBIAL AGENTS AGAINST CAUSATIVE ORGANISMS ISOLATED FROM PATIENTS WITH URINARY TRACT INFECTIONS (2003) II. BACKGROUND OF PATIENTS YOSHIAKI KUMAMOTO*, TAIJI TSUKAMOTO, MASANORI MATSUKAWA and YASUHARU KUNISHIMA Department of Urology, Sapporo Medical University School of Medicine (*: a honorary professor at present) TAKAOKI HIROSE Department of Urology, Hokkaido Social Insurance Hospital OSAMU YAMAGUTI and KEI ISHIBASHI Department of Urology, Fukushima Medical University TATSUO SUZUTANI Department of Microbiology, Fukushima Medical University SHIRO SHIGETA Division, Bureau of Hospital Administration, Fukushima Prefectural Goverment HIROSHI YOSHIDA and YUUJI IMAFUKU Department of Clinical Laboratory Medicine, Fukushima Medical University

Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 555( 67 ) MASARU MURAI Department of Urology, Keio University School of Medicine KIYOAKI WATANABE, YOSHIO KOBAYASHI and HIROSHI UCHIDA Central Clinical Laboratories, Keio University School of Medicine SEIJI MATSUDA Department of Gynecology, Koto Hospital SHINICHI SATO Department of Clinical Laboratories, Koto Hospital TOSHITSUGU OKA and MASAYA KITAMURA Department of Urology Osaka National Hospital YOSHINORI FUKUHARA Department of Clinical Laboratories, Osaka National Hospital SADAO KAMIDONO Division of Urology, Kobe University Graduate School of Medicine SOICHI ARAKAWA Department of Surgical Operation, Kobe University Hospital MAKOTO FUJIME and KAZUHIKO FUJITA Department of Urology, Juntendo University School of Medicine HIROMI KUMON and KOICHI MONDEN Department of Urology, Okayama University Graduate School of Medicine and Dentistry JUN IGARI Urayasu Hospital, Juntendo University School of Medicine TOYOKO OGURI Department of Clinical Laboratories, Juntendo University Hospital KEIZO YAMAGUCHI and NOBUHIKO FURUYA Department of Microbiology, Toho University School of Medicine TAKASHI DEGUCHI and SATOSHI ISHIHARA Urological Devision, Disease Control Course, Gifu University Graduate School of Medicine HIROSHI OOE Department of Urology, Kyoto Second Red Cross Hospital TETSURO MATSUMOTO and KOICHI TAKAHASHI Department of Urology, School of Medicine, University of Occupational and Environmental Health SEIJI NAITO, TOSHIHISA EGASHIRA, and TAKATOSHI KONISHI Department of Urology, Kyushu University Graduate School of Medicine SHIGERU KOHNO Second Department of Internal Medicine, Nagasaki University School of Medicine YOICHI HIRAKATA, AKIRA KONDO, JUNICHI MATSUDA and MICHIKO NAKANO Department of Laboratory Medicine, Nagasaki University Hospital of Medicine and Dentistry MINEKO NISHIKAWA Department of Clinical Laboratory, Kyoto Second Red Cross Hospital YUMIKO SUZUKI Department of Laboratory, Yamada Evidence Research

556( 68 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 Dec. Seven hundred and nineteen bacterial strains isolated from 565 patients diagnosed as having urinary tract infections (UTIs) in 14 institutions in Japan were collected between August 2002 and July 2003. The frequency of bacteria isolation divided with patient clinical background was compared. The clinical background investigated included sex, age, type of infections, timing of antibiotics administration, and presence or absence of surgery affecting a decrease in defense against infection. The bacterial strains were divided with the age and sex of the patients and the types of infections. In males, the number of patients aged less than 50 years was few and the complicated UTIs without indwelling catheter was observed most frequently. Number of patients aged 20 39 years was greater in female than male. In all of ages except 0 9 and 70 79 years, the ratio of the uncomplicated UTIs was high, accounting for 44.4 91.7% of all types of infections. In the present time, the bacteria most frequently isolated were Escherichia coli, Pseudomonas aeruginosa and Enterococcus faecalis also were relatively frequently isolated. E. coli was most frequently isolated from the uncomplicated UTIs, and P. aeruginosa and E. faecalis were frequently isolated from the complicated UTIs with indwelling catheter. With respect to the relation of these results to the age of the patients, in the uncomplicated UTIs, the isolation frequency of E. coli was the highest in all age groups, accounting for 40% or higher. In the complicated UTIs without indwelling catheter, the isolation frequency of E. coli decreased with aging of the patients but still was the highest in all age groups. In the complicated UTIs with indwelling catheter, the isolation frequency of E. coli was lower than in the uncomplicated UTIs in all age groups and P. aeruginosa and E. faecalis were more frequently isolated. In comparison of causative bacteria in UTIs between before and after the administration of antibiotics, P. aeruginosa increased after the administration in any types of UTIs. In comparison of causative bacteria in UTIs with or without surgery, E. coli was more frequently isolated in the patients without surgery, while P. aeruginosa and E. faecalis were more frequently isolated in the patients with surgery in any UTIs.